Research

Adherence

At a population level, distributing GLP-1 medications using less frequent dosing regimens (e.g., every two weeks) allows twice as many obese adults to be treated with the same total drug supply, leading to greater reductions in national obesity rates and mortality compared to standard once-weekly dosing.

This finding is primarily for policymakers and insurers. It suggests that subsidizing GLP-1 drugs for less frequent dosing could save more lives by allowing more people to access treatment. For individual patients, this means that getting on a GLP-1 drug, even at a lower dose or frequency, is better than not getting it at all.

LimitedSupportsLOW confidence
Though scenarios (1) and (2) require the same budget, our analysis suggests that (2) reduces national obesity and mortality to a much greater degree.
Anıl Cengiz et al. · medRxiv · 2024

Why this rating

Based on mathematical modeling and simulation of national health data.

Source

Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy

Anıl Cengiz et al. · medRxiv · 2024

DOI 10.1101/2024.11.27.24318093

preprintCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →